Vital Signs - Avastin vs. Lucentis: Dollars and Sense
Vital Signs - Avastin vs. Lucentis: Dollars and Sense
RELEASE DATE
27-Oct-2008
27-Oct-2008
REGION
North America
North America
Research Code: 9561-00-77-00-00
SKU: HC00550-NA-MR_04022
$1,500.00
In stock
SKU
HC00550-NA-MR_04022
Description
This issue of Vital Signs, released on October 27, 2008, provides an strategic overview of issues surrounding the usage of Avastin and Lucentis in age-related macular degeneration (AMD) patients. Additionally, a company spotlight is provided for Pipex Pharmaceuticals, a developmental stage specialty pharmaceutical company focused on developing its proprietary drug candidates for the treatment of autoimmune diseases and disorders of the central nervous system. Reimbursement and regulatory news from the FDA is also provided for the week of October 13, 2008.
Table of Contents
This week's issue:
Related Research
Popular Topics
This issue of Vital Signs, released on October 27, 2008, provides an strategic overview of issues surrounding the usage of Avastin and Lucentis in age-related macular degeneration (AMD) patients. Additionally, a company spotlight is provided for Pipex Pharmaceuticals, a developmental stage specialty pharmaceutical company focused on developing its proprietary drug candidates for the treatment of autoimmune diseases and disorders of the central nervous system. Reimbursement and regulatory news from the FDA is also provided for the week of October 13, 2008.
No Index | Yes |
---|---|
Podcast | No |
Industries | Healthcare |
WIP Number | 9561-00-77-00-00 |
Is Prebook | No |